Mike Bray

Mike Bray

Auto-generated profile, based on publicly available information

Mike Bray

Chevy Chase, MD, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Antiviral Research
Verified
Journal Article
Closed access
MBMike Bray
Mike Bray
CRCraig Rayner
Craig Rayner
FNFrançois Noël
François Noël
DJDavid Jans
David Jans
KWKylie Wagstaff
Kylie Wagstaff

1 February 2018 in Antiviral Research
Verified
Journal Article
Closed access
JSJessica Spengler
Jessica Spengler
DBDennis A. Bente
Dennis A. Bente
MBMike Bray
Mike Bray
FBFelicity Burt
Felicity Burt
RHRoger Hewson
Roger Hewson
APAnna Papa
Anna Papa

1 September 2003 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
Chad J RoyChad J Roy
Chad J Roy
Robert BakerRobert Baker
Robert Baker
KWKenneth Washburn
Kenneth Washburn
MBMike Bray
Mike Bray
We employed a murine model to test the concept of using an aerosolized, long-acting antiviral drug to protect humans against smallpox. We previously showed that a low dose of aerosolized cidofovir (HPMPC [Vistide]) was highly protective against subsequent aerosolized cowpox virus challenge and was more effective than a much larger dose of drug given by injection, suggesting that aerosolized cidofovir is retained in the lung. Because the nephrotoxicity of cidofovir is a major concern in therapy, delivering the drug directly to the respiratory tract might be an effective prophylactic strategy that maximizes the tissue concentration at the site of initial viral replication, while minimizing its accumulation in the kidneys. In the present study, we found that treating mice with aerosolized 14 C-labeled cidofovir ( 14 C-cidofovir) resulted in the prolonged retention of radiolabeled drug in the lungs at levels greatly exceeding those in the kidneys. In contrast, subcutaneous injection produced much higher concentrations of 14 C-cidofovir in the kidneys than in the lungs over the 96-h time course of the study. As further evidence of the protective efficacy of aerosolized cidofovir, we found that aerosol treatment before or after infection was highly protective in mice challenged intranasally with cowpox virus. All or nearly all mice that were treated once by aerosol, from 2 days before to 2 days after challenge, survived intranasal infection, whereas all placebo-treated animals died.

1 September 2017 in Antiviral Research
Verified
Journal Article
Closed access
Graciela AndreiGraciela Andrei
Graciela Andrei
KCKara Carter
Kara Carter
ZJZlatko Janeba
Zlatko Janeba
ASAruna Sampath
Aruna Sampath
LSLuis Schang
Luis Schang
JEJose Este
Jose Este

1 October 2018 in Antiviral Research
Verified
Journal Article
Closed access
MBMike Bray
Mike Bray
Graciela AndreiGraciela Andrei
Graciela Andrei
EBEster Ballana
Ester Ballana
KCKara Carter
Kara Carter
DDDavid Durantel
David Durantel
JEJose Este
Jose Este

15 October 2022 in Antiviral Research
Verified
Journal Article
Closed access
MBMike Bray
Mike Bray